MRK Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Merck & Co Inc (MRK) is not a strong buy at this moment for a beginner investor with a long-term strategy. While the company has a robust pipeline and positive analyst sentiment, the technical indicators, insider selling, and recent congressional trading data suggest caution. The financial performance shows mixed results, with revenue growth but declining net income and EPS. For a long-term investor, it may be better to wait for a clearer entry point or improved signals.
The MACD is negatively expanding, RSI is neutral, and moving averages are converging, indicating no clear trend. The stock is trading near its S1 support level of 116.219, suggesting limited upside in the short term.
Analysts have consistently raised price targets, with multiple firms maintaining Buy or Outperform ratings. The company's pipeline and upcoming product launches are seen as strong drivers for future growth. Keytruda's patent cliff is being actively managed, and M&A potential remains high.
Insiders are selling, with a 2945.40% increase in selling activity over the last month. Congress members have made only sale transactions in the last 90 days, indicating caution. Financial performance shows declining net income and EPS despite revenue growth. Technical indicators do not suggest a strong upward trend.
In Q4 2025, revenue increased by 4.97% YoY to $16.4B, but net income dropped by 20.84% YoY to $2.96B. EPS declined by 19.59% YoY to $1.19, and gross margin fell by 2.78% YoY to 74.15%.
Analysts are broadly positive, with recent upgrades and price target increases. RBC Capital, Barclays, and Deutsche Bank highlight strong near-term catalysts and a clear path for growth beyond Keytruda's exclusivity loss. Price targets range from $100 to $150, with most firms maintaining Buy or Outperform ratings.
